Cancer treating

Bergstralh DT, Ting JP (2006) Microtubule stabilizing agents their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 32 166-179... 

Hofland LJ, Lamberts SWJ (1997) Somatostatin analogs and receptors. Diagnostic and therapeutic applications. Cancer Treat Res 89 365-382... 

Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004 118 83-100. 

Vermes A et al. Individualisation of cancer therapy based on cytochrome P450 polymorphism a pharmacogenetic approach. Cancer Treat Rev 1997 23 321-339. 

Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. Cancer Treat Rev 2000 26 449-462. Sugiyama Y, Kato Y, Chu X. Cancer Chemother Pharmacol 1998 42(Suppl) S44-S49... 

REF Huguley et al. Cancer Treat Rev 1977 4 261 -273 -there are multiple variations of this regimen... 

Robertson JFR (2004) Selective oestrogen receptor modulators/new antioestrogens a clinical perspective. Cancer Treat Rev 30 695-706... 

Willis KJ, London DR, Ward HW, Butt WR, Lynch SS, Rudd BT (1977) Recurrent breast cancer treated with the antioestrogen tamoxifen correlation between hormonal changes and clinical course. Br Med J 1 425-428... 

Talmadge, J.E. and Herberman, R.B., The preclinical screening laboratory Evaluation of immunomodulatory and therapeutic properties of biological response modifiers, Cancer Treat. Rep., 70, 171, 1986. 

Wheatley, K. et al., Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit A meta-analysis of the randomised trials, Cancer Treat. Rev, 29, 241, 2003. 

Pinsky, C.M. et al., Intravesical administration of Bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder Report of a prospective, randomized trial, Cancer Treat. Rep., 69,47, 1985. 

Bukowski, R. et al. Phase II study of anguidine in gastrointestinal malignancies A Southwest Oncology Group study. Cancer Treat. Rep. 66, 381, 1982. 

Williams, P.D. and Hottendorf, G.H. (1985). Effects of cw-dichlorodiamineplatinum-II (Cisplatin) on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat. Rep. 69 875-880. 

Based on results on thousands of patients who underwent ECT for a variety of tumors, Xin32 has published extensive data in tabular from. Table 1 shows short-term (6 months) efficacy of ECT whereas Table 2 give the long-term cure rate of various cancers treated with ECT. The results, it is claimed,32 are equal to or better than those obtained by other techniques, i.e., surgery, radiation and chemotherapy. It is further claimed32 that ECT can also be applied to patients who cannot be treated by conventional techniques owing to their old age, general poor health, multiple ailments or advances cancers. 

---